Product Information

CALCIUM ACETATE 667 MG CAPSULE is a generic product labeled by Nivagen Pharmaceuticals Inc., priced at $0.1900 per EA under NDC 75834032302. Its NADAC has been published 119 times since Aug 14, 2024.

FDA first approved this application on Mar 13, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

CALCIUM ACETATE 667 MG CAPSULE

Calcium Acetate
$0.1900per EA

Strength

667 mg/1

NDC

75834032302

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Effective Date

11/18/2026

Active Ingredients

CALCIUM ACETATE

Approval Type

Generic (ANDA)

FDA Application

ANDA217205

FDA Approved

3/13/2023

TE Code

AB

On Market Since

12/7/2023

Pharmacological Classes

Blood Coagulation Factor
Calcium
Cations
Divalent
Increased Coagulation Factor Activity
Phosphate Binder
Phosphate Chelating Activity

Price Statistics

The NADAC for CALCIUM ACETATE 667 MG CAPSULE has been published 119 times since Aug 14, 2024, and over the history we have for it it has risen 13.4%. The table below summarizes its recorded NADAC range and movement.

Current price$0.1900 per EA
All-time high$0.2245 (Sep 10, 2025)
All-time low$0.1369 (Nov 20, 2024)
52-week high$0.1900
52-week low$0.1669
Median price$0.1796
Average price$0.1847
Largest weekly change-27.2% (Nov 20, 2024)
Weeks tracked119
Tracking sinceAug 14, 2024

Price History

1W

+8.2%

1M

+12.0%

3M

+13.8%

6M

+9.7%

1Y

+0.0%

3Y

N/A

5Y

N/A

All

+13.4%

Generic Alternatives

The matcher finds 8 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of CALCIUM ACETATE 667 MG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for CALCIUM ACETATE 667 MG CAPSULE, manufactured by Nivagen Pharmaceuticals Inc., is $0.1900 per EA (NDC 75834032302), effective Nov 18, 2026.

How has the price of CALCIUM ACETATE 667 MG CAPSULE changed over time?

Over the history we have for it, the NADAC for CALCIUM ACETATE 667 MG CAPSULE has risen 13.4%. It has been tracked across 119 weekly CMS publications since Aug 14, 2024.

What are the highest and lowest recorded NADAC prices for CALCIUM ACETATE 667 MG CAPSULE?

Since Aug 14, 2024, the NADAC for CALCIUM ACETATE 667 MG CAPSULE has ranged from a low of $0.1369 (Nov 20, 2024) to a high of $0.2245 (Sep 10, 2025), with a median of $0.1796 per EA.

Are there cheaper alternatives to CALCIUM ACETATE 667 MG CAPSULE?

8 manufacturers publish a NADAC-priced product with the same active ingredient and strength as CALCIUM ACETATE 667 MG CAPSULE in a comparable dosage form, but none are currently priced below it.

Who manufactures CALCIUM ACETATE 667 MG CAPSULE?

CALCIUM ACETATE 667 MG CAPSULE (NDC 75834032302) is labeled by Nivagen Pharmaceuticals Inc., and CMS classifies it as a generic product.